Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 44, 2014 - Issue 5
352
Views
2
CrossRef citations to date
0
Altmetric
Clinical Pharmacokinetics and Metabolism

Metabolism and clinical pharmacokinetics of 2-methyl-n-(2′-(pyrrolidinyl-1-ylsulfonyl)-n-[1,1′-biphenyl]-4-yl)propran-1-amine: insights into monoamine oxidase- and CYP-mediated disposition by integration of in vitro ADME tools

, , , , , , , , , , , & show all
Pages 438-454 | Received 12 Jul 2013, Accepted 27 Sep 2013, Published online: 04 Dec 2013
 

Abstract

1. In early discovery stages, 2-methyl-N-(2′-(pyrrolidinyl-1-ylsulfonyl)-[1,1′-biphenyl]-4-yl)propan-1-amine (PBPA) demonstrated monoamine oxidase A (MAO-A) and cytochrome P450 (CYP)-mediated clearance. While human liver microsomes predicted low CLb PBPA demonstrated a moderate CLp/F in humans. The plasma pharmacokinetic (PK) of PBPA was characterized by unexpected high inter-individual variability. Hence, a retrospective analysis was undertaken to understand the disposition processes of PBPA, by applying in vitro mechanistic tools.

2. The in vitro-to-in vivo of rat CLb of PBPA was calculated as similar to that of human, suggesting rat to be a better predictor of a MAO-A/CYP substrate, but not dog or monkey; this is consistent with differences in expression of MAO-A in rat, dog, monkey and human. Fraction metabolized (fm) of human MAO A (hMAO-A) (50%), CYP3A4 (8%), CYP3A5 (16%) and CYP2D6 (29%) was determined, in vitro.

3. While the fm of CYP3A5 was <50%, Michaelis–Menten kinetics demonstrated that it was a higher capacity pathway compared with MAO-A, 2D6 and 3A4. This was consistent with strong association of dose-normalized plasma Cmax and area under the plasma concentration time curve (AUC0-tlast) of PBPA with CYP3A5 genotype, but not with genotype of CYP2D6.

4. This investigation demonstrates the value of integrating in vitro mechanistic tools to gain comprehensive understanding of disposition properties of drug candidates, in a discovery paradigm and prior to the investment in clinical trials.

Acknowledgements

The authors would like to acknowledge the contributions of Julie Poe, Dr Joanne Brodfuehrer, Dr Alfin Vaz and Dr Jennifer Liras at Pfizer Global Research and Development.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.